KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for CRISPR Therapeutics AG (CRSP) over the last 5 years, with Q3 2025 value amounting to $28.4 million.

  • CRISPR Therapeutics AG's Long-Term Investments changed N/A to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.4 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2023, which is 9623.56% down from last year.
  • CRISPR Therapeutics AG's Long-Term Investments amounted to $28.4 million in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Long-Term Investments ranged from a high of $77.1 million in Q3 2022 and a low of $2.0 million during Q4 2023
  • Moreover, its 4-year median value for Long-Term Investments was $9.8 million (2022), whereas its average is $23.9 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Long-Term Investments tumbled by 9623.56% in 2023, and later skyrocketed by 12885.13% in 2024.
  • Quarter analysis of 4 years shows CRISPR Therapeutics AG's Long-Term Investments stood at $53.1 million in 2022, then plummeted by 96.24% to $2.0 million in 2023, then skyrocketed by 460.8% to $11.2 million in 2024, then surged by 153.32% to $28.4 million in 2025.
  • Its last three reported values are $28.4 million in Q3 2025, $11.2 million for Q2 2024, and $2.0 million during Q4 2023.